Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro

Glioblastoma is a disease characterized by rapid invasive tumour growth. Studies on the proapoptotic CD95/CD95L signalling pathway recently suggested a significant contribution of CD95 signalling towards the high degree of motility in glioma cells. Apogenix has developed APG101, a clinical phase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Merz, Christian, Strecker, Alexander, Sykora, Jaromir, Hill, Oliver, Fricke, Harald, Angel, Peter, Gieffers, Christian, Peterziel, Heike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Preclinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484665/
https://www.ncbi.nlm.nih.gov/pubmed/25850884
http://dx.doi.org/10.1097/CAD.0000000000000237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484665/
https://www.ncbi.nlm.nih.gov/pubmed/25850884
http://dx.doi.org/10.1097/CAD.0000000000000237

Ejemplares similares